Trends in the use of aspirin and nonsteroidal anti‐inflammatory drugs in the general U.S. population
Top Cited Papers
- 30 May 2013
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 23 (1), 43-50
- https://doi.org/10.1002/pds.3463
Abstract
Purpose The objective of this study was to describe trends in the prevalence of regular aspirin and nonsteroidal anti-inflammatory drug (NSAID) use among adults in the United States during 2005 and 2010, and to identify characteristics of regular users. Methods Data from the 2005 and 2010 National Health Interview Survey (NHIS) were analyzed to estimate the prevalence of regular use of aspirin and NSAIDs among U.S. adults aged 18 years and older. Results were stratified by demographics and self-reported medical conditions and extrapolated to provide U.S. population estimates. Results In 2010, around 43 million adults (19.0%) took aspirin at least three times per week for more than 3 months (i.e. regular users), and more than 29 million adults (12.1%) were regular users of NSAIDs. Compared with 2005, this was an overall increase of 57% in aspirin use and 41% in NSAID use. These increases were consistent across the strata of age, sex, race, and selected medical conditions, including cardiovascular disease (CVD), arthritis, peptic ulcers, cancer, and severe headache, except for Asian Americans. Conclusion Large increases in the use of both aspirin and NSAIDs were observed over a 5 year period. The increase may be the result of increasing media attention reporting that regular aspirin use lowers the risk of CVD and related deaths, and may also prevent cancer. Moreover, safety concerns related to alternative medications such as acetaminophen and selective COX-2 inhibitors may influence users of these drugs to switch to aspirin and NSAIDs. Copyright © 2013 John Wiley & Sons, Ltd.Keywords
This publication has 52 references indexed in Scilit:
- Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trialsThe Lancet, 2012
- Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trialsThe Lancet, 2012
- Aspirin for the prevention of colorectal cancerBest Practice & Research Clinical Gastroenterology, 2011
- Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort studyBreast Cancer Research and Treatment, 2010
- Non‐aspirin NSAIDs, cyclooxygenase‐2 inhibitors and risk for cardiovascular events–stroke, acute myocardial infarction, and death from coronary heart diseasePharmacoepidemiology and Drug Safety, 2009
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Use of Anti-Inflammatory Drugs and Lower Esophageal Sphincter–Relaxing Drugs and Risk of Esophageal and Gastric CancersClinical Gastroenterology and Hepatology, 2007
- Aspirin in the treatment and prevention of cardiovascular disease: Current perspectives and future directionsCurrent Atherosclerosis Reports, 2007
- Gender Differences in Aspirin use Among Adults With Coronary Heart Disease in the United StatesJournal of General Internal Medicine, 2007
- Long-term Use of Aspirin and Nonsteroidal Anti-inflammatory Drugs and Risk of Colorectal CancerJAMA, 2005